Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 1998-2008

  Tolmachev, Vladimir ^a   Malmberg, Jennie ^b   Estrada, Sergio ^b   Eriksson, Olof ^b   Orlova, Anna ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Iodine 124; Molecular imaging; PET; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

CAPROMAB; CAPROMAB I 124; CAPROMAB I 125; CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; IODINE 124;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE; CANCER STAGING; COLON; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; GAMMA COUNTER; ISOTOPE LABELING; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOIODINATION; SENSITIVITY ANALYSIS; SPLEEN; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; EXPERIMENTAL NEOPLASM; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SCINTISCANNING; SECONDARY; TISSUE DISTRIBUTION; TUMOR CELL LINE; ANIMAL TISSUE; DRUG BINDING; IN VITRO STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; LYMPHATIC METASTASIS; MALE; MICE; NEOPLASM STAGING; NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84899535976     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2376     Document Type: Article

References (31)

1. Takahashi N, Inoue T, Lee J, Yamaguchi T and Shizukuishi K: The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 2: 226-233, 2007.
2. Lawrentschuk N, Davis ID, Bolton D-M and Scott AM: Positron emission tomography and molecular imaging of the prostate: an update. BJU Int 97: 923-931, 2006.
3. Beresford MJ, Gillatt D, Benson RJ and Ajithkumar T: A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 22: 46-55, 2010.
4. 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 102: 446-451, 2008.
5. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 99: 1415-1420, 2007.
6. Lilja H, Ulmert D and Vickers AJ: Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8: 268-278, 2008.
7. Raff AB, Gray A and Kast WM: Prostate stem cell antigen: A prospective therapeutic and diagnostic target. Cancer Lett 277: 126-132, 2009.
8. Silver DA, Pellicer I, Fair WR, Heston WD and Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81-85, 1997.
9. Ulmert D, Evans MJ, Holland JP, et al: Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov 2: 320-327, 2012.
10. Manyak MJ: Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther 8: 175-181, 2008.
11. Miyamoto DT, Lee RJ, Stott SL, et al: Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2: 995-1003, 2012.
12. Eder M, Eisenhut M, Babich J and Haberkorn U: PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 40: 819-823, 2013.
13. Manya MJ, Hinkle GH, Olsen JO, et al: Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 54: 1058-1063, 1999.
14. Van Dongen GA and Vosjan MJ: Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 25: 375-385, 2010.
15. 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 19: 155-163, 2004.
16. Nagengast WB, de Vries EG, Hospers GA, et al: In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48: 1313-1319, 2007.
17. 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 35: 1857-1867, 2008.
18. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50: 974-981, 2009.
19. 89Zr- bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 51: 761-767, 2010.
20. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 50: 417-425, 2009.
21. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87: 586-592, 2010.
22. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8: 304-310, 2007.
23. 89Zr-7E11 immuno-PET. J Nucl Med 52: 1608-1615, 2011.
24. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51: 1293-1300, 2010.
25. Barren RJ III, Holmes EH, Boynton AL, Misrock SL and Murphy GP: Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 30: 65-68, 1997.
26. Tolmachev V and Orlova A: Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr Med Chem 17: 2636-2355, 2010.
27. Koziorowski J, Henssen C and Weinreich R: A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for iodination of proteins. Appl Radiat Isot 49: 955-959, 1998.
28. Lindmo T, Boven E, Cuttila F, Fedorko J and Bunn PA Jr: Determination of immunoractive fraction of radiolabeled monoclonal antibody by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77-89, 1984.
29. Khaw BA, Cooney J, Edgington T and Strauss HW: Differences in experimental tumor localization of dual-labeled monoclonal antibody. J Nucl Med 27: 1293-1239, 1986.
30. Meijs WE, Haisma HJ, Klok RP, van Gog FB, Kievit E, Pinedo HM and Herscheid JD: Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med 38: 112-118, 1997.
31. 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. Nucl Med Biol 38: 1093-1102, 2011.